A Review on Personalized Medicine and Pharmacogenomics

Mr. Shinde Nilesh N[1], Mr. Pathan Ayaj S[1], Ms. Swami Vaishnavi B[2*], Ms. Salgar Rupali C[2], Ms. Jadhav Sneha P[2], Ms. Surwase Sneha R[2], Ms. Jadhav Nikita B[2], Ms. Gonare Pratiksha B[2], Mr. Suryawanshi Vishal V[2]

[1]*Assistant Professor Department of Pharmacy at Godavari Institute of Pharmacy Kolpa, Latur-413512, Maharashtra, India*

[2]*Student Department of Pharmacy at Godavari Institute of Pharmacy Kolpa, Latur- 413512, Maharashtra, India*

Abstract: Personalized medicine is revolutionizing healthcare by tailoring treatments to the unique genetic, environmental, and lifestyle characteristics of each individual. One key component of personalized medicine is pharmacogenomics, which investigates how genetic variations affect an individual's response to drugs. This paper delves into the convergence of personalized medicine and pharmacogenomics, emphasizing the potential of these fields to enhance therapeutic outcomes, reduce adverse drug reactions, and lower healthcare costs. Additionally, it explores the challenges and opportunities associated with incorporating pharmacogenomics into clinical practice, the ethical considerations involved, and the future direction of personalized healthcare.

Personalized medicine is a versatile field that can be applied in the diagnosis and treatment of various diseases such as cancer, Alzheimer's, hepatitis, and cardiovascular conditions. It is an emerging area of medical science, offering considerable promise for the future. This review focuses on the characteristics of personalized medicine and its implementation in specific diseases like lung cancer, renal cancer, and rheumatoid arthritis. Furthermore, the paper addresses initiatives taken by the European Union to promote the development of personalized medicine and discusses the challenges encountered during data collection, drug development, and clinical trials. Additionally, the Personalized Medicine Coalitions (PMC) have approved several novel drugs as personalized treatments under the approval of the US FDA.

Keywords: Personalized Medicine, Pharmacogenomics, Genetic Variations, Drug Response, Therapeutic Outcomes, Adverse Drug Reactions, Genetic Testing, Precision Medicine.

INTRODUCTION

Personalized medicine, or precision medicine, tailors treatments to the individual characteristics of each patient, including their genetic makeup, lifestyle, and environment. Unlike the traditional one-size-fits-all approach, it aims to provide the most effective treatment based on these factors. A key element of personalized medicine is pharmacogenomics, which studies how genetic variations impact drug metabolism, efficacy, and toxicity.

With advancements in genomics and decreasing costs of genetic testing, personalized medicine holds great promise. Pharmacogenomics helps optimize drug therapy by ensuring the right medication is prescribed at the right dose, enhancing treatment outcomes and reducing the risk of adverse drug reactions (ADRs), which are a leading cause of morbidity and mortality. Personalized treatments can be tailored to individual patients or groups, combining modern molecular techniques with traditional methods for more accurate diagnosis and therapy. Today, diagnoses are increasingly based on genetic markers linked to specific diseases, improving accuracy and treatment precision.

The Role of Pharmacogenomics in Personalized Medicine:

Pharmacogenomics merges pharmacology and genomics to explore how genetic factors impact the body's response to medications. These genetic variations can influence drug absorption, distribution, metabolism, elimination, and pharmacodynamics (the

effects of drugs on the body). Key areas where pharmacogenomics can be applied include:

Drug Metabolism: Enzymes like cytochrome P450 (CYP) are crucial in the metabolism of many medications. Genetic variations in these enzymes can result in differences in how a drug is processed. For instance, patients with genetic polymorphisms that cause faster drug metabolism may need higher doses to reach therapeutic levels, while individuals with slower metabolism may experience harmful side effects even at standard doses.

Drug Efficacy: Genetic variations can also impact drug targets, such as receptors or enzymes with which the drug interacts. For example, mutations in the gene that codes for the enzyme thiopurine methyltransferase (TPMT) can influence how a patient responds to thiopurine medications, which are used to treat leukemia, autoimmune disorders, and organ transplant rejection.

Adverse Drug Reactions (ADRs): Adverse drug reactions (ADRs) are a significant concern in clinical practice. By identifying genetic factors that make individuals more susceptible to ADRs, pharmacogenomics can help reduce their occurrence. For example, genetic variations in the HLA-B gene have been associated with adverse reactions to abacavir, a drug commonly used in HIV treatment. Testing for these genetic markers before prescribing the medication can help prevent severe allergic reactions.

The role of personalized medicine:

The role of personalized medicine lies in tailoring healthcare treatments to the unique genetic, environmental, and lifestyle characteristics of each patient. Unlike traditional approaches that apply a uniform treatment to all patients, personalized medicine seeks to optimize therapeutic outcomes by considering individual variations. This approach not only improves the effectiveness of treatments but also reduces the risk of adverse drug reactions, as medications can be adjusted based on genetic factors that influence drug metabolism and response.

Personalized medicine also extends to the prevention, diagnosis, and management of diseases. It allows for early detection of conditions through genetic testing, enabling more precise and timely interventions. In areas such as cancer, cardiovascular diseases, and rare genetic disorders, personalized medicine can offer targeted therapies that are more likely to succeed compared to conventional treatments. As genetic research and technology continue to advance, personalized medicine holds the potential to revolutionize healthcare by providing more individualized, efficient, and cost-effective care.

Implementation of Pharmacogenomics in Clinical Practice:

Genetic Testing in Pharmacogenomics:

Genetic testing plays a crucial role in the effectiveness of pharmacogenomics. With advancements in next-generation sequencing (NGS) and other genomic technologies, genetic testing has become more accessible and affordable. This testing is used to identify genetic variations in drug-metabolizing enzymes, receptors, transporters, and markers related to drug toxicity. Despite these advancements, several challenges remain in the widespread adoption of genetic testing. These include the high cost of testing, the absence of standardized procedures for testing and interpreting results, and the need for healthcare professionals to receive proper training in pharmacogenomics.

Clinical Decision Support Systems:

Clinical decision support systems (CDSS) that incorporate pharmacogenomic data into electronic health records (EHR) are becoming more prevalent. These systems assist healthcare providers by alerting them to potential drug-gene interactions, suggesting alternative therapies, and aiding in dosage adjustments based on an individual's genetic profile.

Guidelines and Regulatory Approvals:

Several professional organizations and regulatory bodies, including the U.S. Food and Drug Administration (FDA), have issued guidelines and recommendations on pharmacogenomic testing. The FDA has approved pharmacogenomic-based drug labeling for numerous medications, and the availability of such information is expected to expand as more drugs are tested and evaluated for genetic factors.

PERSONALISED MEDICINE FOR LUNG CANCER

Systemic treatments for lung cancer are often limited, but targeted therapies have become more common in recent years. Drugs such as monoclonal antibodies

(mAbs) and tyrosine kinase inhibitors (TKIs) are actively used to target the epidermal growth factor receptor (EGFR), achieving a response rate of over 70%. However, studies have shown that, in some cases, these targeted therapies may worsen the condition more than traditional cytotoxic drugs, and they tend to be significantly more expensive.

Non-small cell lung cancer (NSCLC) is a leading cause of cancer, characterized by uncontrolled cell growth. One promising approach in personalized medicine for cancer management is the use of positron emission tomography (PET) and radio-labeled drugs. By regularly assessing metabolites and pharmacokinetics through blood and urine samples, the effectiveness of treatments can be monitored. PET is a powerful imaging technique that creates three-dimensional (3D) images using gamma rays. This method offers the advantage of targeting disease sites more precisely with radio-labeled drugs, which aids in the development of targeted therapies for personalized treatment.

The pharmacokinetics (PK) of targeted drugs are studied to create new medications, and the binding of radio-labeled drugs to tumors can also be predicted. Immuno-PET, a type of imaging system used in antigen therapy, employs mAbs that are labeled with radionuclides such as 89Zr. However, due to the slower pharmacokinetics of radio-labeled mAbs, dynamic scanning is challenging, making it difficult to obtain real-time data during imaging.

Personalized Medicine in Drug Development:

Critics argue that customized drugs and biomarkers may not serve as the driving force behind the next generation of medications, suggesting that the concept is merely a rebranding of basic tools used to explore biology. However, it has long been established that biomarkers are integral to effective clinical diagnostics and practice, serving as indicators of potential health risks. For instance, traditional biomarkers like blood pressure and serum cholesterol are widely used to assess the risk of cardiovascular diseases.

Despite challenges in accurately defining and accessing emerging technologies and biomarker science, biomarkers have seen recent success in regulatory approvals. These biological markers are essential not only for developing safe and effective drugs but also for determining which patients should receive specific treatments and at what times. Personalized drug development often involves collaboration between patients and researchers, with genetic research playing a key role in understanding individual drug responses due to genetic variations.

Molecular analysis of deoxyribonucleic acid (DNA) can provide patient-specific information about receptors and enzymes relevant to a particular drug. This allows for predictions regarding how the drug will affect a patient before they even begin treatment. Such insights enable tailored recommendations for treatment, lifestyle changes, and disease prevention, ensuring that the right drug is given to the right patient at the optimal dose.

The application of genetic insights is not confined to complex diseases like cancer and HIV. In fact, up to 35% of the population with cardiovascular disease may not respond to statins, as seen by the lack of changes in arterial wall thickness. However, it remains uncertain whether patients would accept being labeled as "non-responders" without trying alternative treatments, especially when no other options are available for their condition. The National Health Service (NHS) might consider funding statins for patients who are advised they are non-responders based on genetic results.

A cost-effectiveness analysis comparing personalized medicine to the traditional public health approach suggests that the personalized approach may be the way forward for improving health outcomes and reducing unnecessary treatments.

Application of Personalized Medicine:

1. Diagnosing disease earlier in development using optimal surveillance, thereby allowing more effective interventions or treatment options.
2. Avoiding preventable drug related complications and side effects resulting from generic “one size fits all” drug prescribing.
3. By ensuring appropriate drug is used and that the dosing regimen takes into consideration any genetic variants enhance the therapeutic efficacy which may affect metabolism of the drug.
4. If someone is at increased risk of developing a disease, followed by promotion of and support for compliance with available prevention strategies.

Challenges in Personalized Medicine and Pharmacogenomics:

Ethical, Legal, and Social Considerations:

The incorporation of pharmacogenomics into healthcare presents a number of ethical challenges, especially in areas like privacy, consent, and genetic discrimination. Genetic testing can uncover information that not only affects the individual but may also have implications for their family members. As genetic data becomes an essential component of clinical decision-making, safeguarding this information and ensuring its responsible use is crucial.

Health Disparities:

The advantages of pharmacogenomics may not be equally accessible to all populations. Much of the existing pharmacogenomic research has focused on individuals of European descent, and the genetic variations influencing drug responses may differ in other populations. This disparity poses a challenge in ensuring that pharmacogenomic testing is both accurate and applicable across diverse groups of patients.

Cost and Accessibility:

The cost of genetic testing and the lack of reimbursement policies for pharmacogenomic testing in certain areas can limit patient access to these services. Additionally, the integration of pharmacogenomics into everyday clinical practice requires substantial investment in both infrastructure and training for healthcare providers. This can create barriers to widespread adoption and use of pharmacogenomic technologies.

Key Features of Personalized Medicine:

1. Definition of Personalized Medicine (PM): Personalized Medicine (PM) refers to any technology aimed at improving the prevention, diagnosis, and treatment of diseases by utilizing individual patient characteristics to determine the most suitable care options.
2. Diagnostic Testing: Personalization of treatment requires additional patient-specific information, which is gathered through diagnostic testing. This may involve technologies like molecular diagnostics, gene sequencing (such as next-generation sequencing), or immunohistochemistry assays.
3. Incorporation of Various Technologies: A wide range of medical technologies are integrated into personalized medicine, including small molecule drugs, large molecules (biologics), and advanced therapy medicinal products (ATMPs).
4. Individualized Therapies: These therapies, such as modified T-cell therapies and gene therapies, are classified as ATMPs. These treatments are designed to address the specific needs of individual patients.
5. Targeted Treatments: Treatments are tailored to vary between individuals with the same disease, as personalized care recognizes the distinct genetic and molecular characteristics of each patient.
6. Targeted Therapies: Targeted therapies focus on specific molecular targets associated with diseases. These targets may be derived from particular mutations or from proteins that are expressed within certain biological pathways. In oncology, for example, targeted therapies work through various mechanisms, such as inhibiting cell proliferation, inducing necrosis, suppressing metastasis, and modulating immune functions.

Recent organizational efforts:

Under the leadership of FDA Commissioner Dr. Margaret A. Hamburg, the FDA has strengthened its commitment to advancing personalized medicine. In 2011, Dr. Hamburg introduced a restructuring of the Commissioner's Office and the agency's programs into four key "directorates." As part of this initiative, a new role—Deputy Commissioner for Medical Products and Tobacco—was created, along with an office to provide top-level coordination across the centers for drugs, biologics, medical devices, and tobacco products, as well as to oversee the Office of Special Medical Programs. This management restructure was designed to address the agency's expanding responsibilities in a complex environment, where products and services no longer fit neatly into a single category. By consolidating programs with shared regulatory and scientific foundations, the FDA aims to become a more effective catalyst for innovation and to tackle the scientific and regulatory challenges of emerging fields such as personalized medicine.

Each of the medical product centers has significantly enhanced its focus on personalized medicine under the current administration. The Genomics and Targeted Therapy Group in the Center for Drug Evaluation and Research (CDER) has expanded its capacity, while the Offices of Biostatistics, New Drugs, and Translational Sciences have appointed leaders to focus on pharmacogenomics and biomarker development. In

2009, the Center for Devices and Radiological Health (CDRH) established a Personalized Medicine staff to address both the opportunities and challenges posed by diagnostics in personalized medicine. Additionally, CDRH's Office of Science and Engineering Laboratories (OSEL) has created a high-performance computing facility to support data processing and computational modeling efforts.

The Future of Personalized Medicine and Pharmacogenomics:

The future of personalized medicine and pharmacogenomics holds great promise. With advancements in large-scale genomic research, machine learning, and artificial intelligence, we can anticipate more precise and efficient drug development. The use of genomics to identify biomarkers for diseases and drug responses is likely to lead to the creation of novel, targeted therapies.

Furthermore, the integration of pharmacogenomics into everyday clinical practice will continue to progress. As genomic data becomes more widely accessible and healthcare providers gain deeper expertise, personalized treatments based on individual genetic profiles are expected to become the standard of care.

The FDA has already approved numerous medicines based on their innovative approaches, and it is likely to continue approving such therapies in the future. Personalized medicine blends clinical and family history, providing a novel and promising tool for drug development.

However, the field faces significant challenges. High costs, insufficient information, and lack of public awareness pose obstacles that need to be addressed. The development of these therapies can be time-consuming and requires sophisticated commercial techniques. Despite these challenges, personalized medicine offers great potential, especially for developing countries.

For personalized medicine to be a successful approach for early disease detection and treatment, it is essential for individuals, especially future healthcare professionals, to be proactive and engaged. By doing so, they will be better equipped to tackle the challenges and make personalized medicine accessible to all.

CONCLUSION

Personalized medicine and pharmacogenomics have the potential to revolutionize healthcare by optimizing drug therapies, enhancing patient outcomes, and minimizing adverse drug reactions. Despite the challenges in implementing these technologies, continuous advancements in genomic research, clinical decision support systems, and healthcare infrastructure will help pave the way for a future where personalized medicine is a foundational element of clinical practice. With ongoing research and careful attention to ethical, legal, and social considerations, pharmacogenomics will be pivotal in shaping the future of healthcare.

Personalized medicine introduces a new paradigm for drug development and medical practice. While the promise of personalized medicine includes the creation of safer and more effective drugs for specific disease populations, these benefits will only be realized once certain barriers to its widespread adoption are overcome. Public policy challenges include unclear regulatory frameworks, insufficient insurance coverage for diagnostic tests tied to preventive care, gaps in legal protections against genetic discrimination, and a lack of comprehensive healthcare information technology systems. Additionally, the current medical education system has yet to adequately equip physicians with the knowledge needed to integrate personalized medicine diagnostics or pharmacogenomics into their practices.

Personalized medicine (PM) is a modern approach to understanding, classifying, treating, and preventing disease based on individual biological and environmental differences. The true challenge of personalized medicine lies in how it addresses social factors, setting criteria for equity and resource distribution, which must be carefully evaluated. Education in PM is essential for its success, and overcoming these challenges will require well-designed projects and strategies that align with public needs and priorities. Achieving this is a difficult but crucial task for ensuring the optimal success of treatment outcomes.

REFERENCE

[1] Elewa H, Awaisu A. Pharmacogenomics in pharmacy practice: current perspectives. Integrated Pharmacy Research and Practice. 2019 Nov 8:97-104.

[2] Akhondzadeh S. Personalized medicine: a tailor made medicine. Avicenna Journal of Medical Biotechnology. 2014 Oct;6(4):191.
[3] Wilsdon T, Barron A, Edwards G, Lawlor R. The benefits of personalised medicine to patients, society and healthcare systems. Boston, MA: Charles River Associates. 2018 Jul.
[4] Abrahams E, Ginsburg GS, Silver M. The personalized medicine coalition: goals and strategies. American Journal of Pharmacogenomics. 2005 Dec;5:345-55..
[5] Di Sanzo M, Cipolloni L, Borro M, La Russa R, Santurro A, Scopetti M, Simmaco M, Frati P. Clinical applications of personalized medicine: a new paradigm and challenge. Current pharmaceutical biotechnology. 2017 Mar 1;18(3):194-203.
[6] Anaya JM, Duarte-Rey C, Sarmiento-Monroy JC, Bardey D, Castiblanco J, Rojas-Villarraga A. Personalized medicine. Closing the gap between knowledge and clinical practice. Autoimmunity reviews. 2016 Aug 1;15(8):833-42.
[7] Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015 Oct 15;526(7573):343-50.
[8] Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U. Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR Personalized Medicine Special Interest Group. Value in Health. 2012 Dec 1;15(8):1162-71.
[9] Scandolara TB, Barreto Pires BR, Vacario B, de Amorim IS, Siqueira PB, Serpeloni JM, Mencalha AL, Bonvicino CR, Panis C. An overview regarding pharmacogenomics and biomarkers discovery: focus on breast cancer. Current Topics in Medicinal Chemistry. 2022 Aug 1;22(20):1654-73.
[10] Kim JA, Ceccarelli R, Lu CY. Pharmacogenomic biomarkers in US FDA-approved drug labels (2000–2020). Journal of personalized medicine. 2021 Mar 4;11(3):179.
[11] Kowal S, Luth W. Terminology for Personalized Medicine: a systematic collection.
[12] Francis S, Ross A. Introduction to the devout life. Courier Corporation; 2009 Mar 26.
[13] Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New biotechnology. 2012 Sep 15;29(6):613-24.
[14] Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM. The growing role of precision and personalized medicine for cancer treatment. Technology. 2018 Sep 11;6(03n04):79-100.
[15] Abrahams E, Ginsburg GS, Silver M. The personalized medicine coalition: goals and strategies. American Journal of Pharmacogenomics. 2005 Dec;5:345-55.
[16] Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annual review of genomics and human genetics. 2011 Sep 22;12(1):217-44.
[17] Jakka S, Rossbach M. An economic perspective on personalized medicine. The HUGO Journal. 2013 Dec;7:1-6.
[18] Bauer DC, Gaff C, Dinger ME, Caramins M, Buske FA, Fenech M, Hansen D, Cobiac L. Genomics and personalised whole-of-life healthcare. Trends in molecular medicine. 2014 Sep 1;20(9):479-86.